Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 2Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Hepatocellular 6Esophageal Squamous Cell Carcinoma 5Carcinoma, Non-Small-Cell Lung 5Esophageal Neoplasms 3Advanced Solid Tumor 3Stomach Neoplasms 2Lung Neoplasms 2Cholangiocarcinoma 2Advanced Lung Cancer 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous NSCLC 1Solid Tumor 1SCLC 1Recurrence 1Rectal Neoplasms 1Ovarian Neoplasms 1Non-Squamous Non-Small Cell Lung Cancer 1Neoplasms, Unknown Primary 1Neoplasms, Squamous Cell 1Neoplasms 1Neoplasm Metastasis 1Locally Advanced Rectal Cancer 1Liver Neoplasms 1Liver Diseases 1High-Risk Resectable NSCLC 1Gastrointestinal Diseases 1Esophageal Diseases 1Endometrial Neoplasms 1Colorectal Neoplasms 1

Interventions

Cyclophosphamide 67Dexamethasone 52Peripheral Blood Stem Cell Transplantation 37Lenalidomide 37Rituximab 35fludarabine phosphate 34Bortezomib 30Filgrastim 27Etoposide 27Cytarabine 25Carboplatin 25Busulfan 23Radiotherapy 22Melphalan 22Gemcitabine 22Cyclosporine 21pomalidomide 20fludarabine 20Whole-Body Irradiation 20Mycophenolic Acid 20Paclitaxel 19Methotrexate 18venetoclax 17Cisplatin 17pembrolizumab 16Calcium Dobesilate 16Bevacizumab 16Tacrolimus 14Antilymphocyte Serum 14Nivolumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Recurrence × sintilimab × Clear all
NCT03989336 2024-07-15

A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer

Chinese PLA General Hospital

Phase 2 Completed
84 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡